Sign in

    Jeff Zekauskas

    Managing Director and Senior Equity Research Analyst at JPMorgan Chase & Co.

    Jeff Zekauskas is a Managing Director and Senior Equity Research Analyst at JPMorgan Chase & Co., specializing in the chemicals and basic materials sectors. He covers major companies such as Albemarle, Celanese, Compass Minerals International, Westlake, Orion, Generac, and Eastman Chemical, and has maintained a 56% rate of profitable recommendations with an average return per transaction of 5.10%. With a research career at JPMorgan dating back to 2000, Zekauskas is recognized as a Hall of Fame All-America Research Team analyst and is consistently ranked among the top chemical sector analysts on prominent investment research platforms. He holds relevant professional credentials and securities licenses, including FINRA registration.

    Jeff Zekauskas's questions to FULLER H B (FUL) leadership

    Jeff Zekauskas's questions to FULLER H B (FUL) leadership • Q2 2025

    Question

    Jeff Zekauskas asked several housekeeping questions regarding the source of acquisition project costs in the quarter and the amount of pension income. He also sought clarification on whether raw material costs were declining sequentially and if overall business demand was steady outside of the noted weakness in residential construction.

    Answer

    EVP & CFO John Corcoran clarified that the acquisition costs were lingering from the flooring divestiture and provided the quarterly pension income figure. President & CEO Celeste Mastin confirmed that raw materials are declining sequentially, though still up year-over-year, and that demand outside of U.S. residential construction was generally stable and consistent, with particular strength in roofing.

    Ask Fintool Equity Research AI

    Jeff Zekauskas's questions to SEALED AIR CORP/DE (SEE) leadership

    Jeff Zekauskas's questions to SEALED AIR CORP/DE (SEE) leadership • Q4 2024

    Question

    Jeff Zekauskas asked for a breakdown of the Protective segment's 2024 performance, specifically the growth rates for its industrial and e-commerce sides and the current revenue split. He also asked for an explanation of the year-over-year decrease in cost of goods sold.

    Answer

    CEO Dustin Semach stated the Protective segment is roughly 60% industrial and 40% fulfillment. In 2024, the industrial portfolio volume was down low-to-mid single digits, while fulfillment was down mid-to-high single digits. Interim CFO Veronika Johnson explained the reduction in COGS correlated with the overall sales decline but was also aided by favorability in raw material pricing. Semach added that cost takeout actions and productivity also contributed significantly to the COGS reduction.

    Ask Fintool Equity Research AI

    Jeff Zekauskas's questions to SEALED AIR CORP/DE (SEE) leadership • Q4 2024

    Question

    An analyst on behalf of Jeff Zekauskas asked for a breakdown of the Protective segment's 2024 performance, including the growth rates for its industrial and e-commerce sides and the current revenue split. A second question asked for the drivers behind the year-over-year decrease in cost of goods sold, questioning if it was due to raw materials or cost reductions.

    Answer

    CEO Dustin Semach stated the Protective segment is roughly 60% industrial and 40% fulfillment. In 2024, the industrial portfolio's volume was down low-to-mid single digits, while fulfillment was down mid-to-high single digits. Interim CFO Veronika Johnson addressed the COGS question, explaining the decrease correlated with lower sales but was also aided by favorable raw material pricing. Semach added that a significant portion of the company's cost takeout actions also benefited COGS.

    Ask Fintool Equity Research AI

    Jeff Zekauskas's questions to INTERNATIONAL FLAVORS & FRAGRANCES (IFF) leadership

    Jeff Zekauskas's questions to INTERNATIONAL FLAVORS & FRAGRANCES (IFF) leadership • Q3 2024

    Question

    Jeff Zekauskas of JPMorgan Chase & Co. asked for clarification on October volume trends, questioning if they were up mid-single digits. He also inquired about the profitability of the Functional Ingredients business, asking if its EBITDA was growing this year.

    Answer

    CFO Glenn Richter confirmed that October volumes were up mid-single digits, consistent with the pattern of recent quarters. For Functional Ingredients, he stated that while currency-neutral sales are flattish due to price givebacks, gross margins are up nicely and EBITDA is up 'very strongly.' He noted the segment's EBITDA margin will likely finish the year north of 12%, up from circa 8-9% last year, on its way to a mid-teens target.

    Ask Fintool Equity Research AI

    Jeff Zekauskas's questions to FMC (FMC) leadership

    Jeff Zekauskas's questions to FMC (FMC) leadership • Q3 2024

    Question

    Jeff Zekauskas of JPMorgan Chase & Co. asked about the sharp price decline of a generic diamide active ingredient (CTPR) in China, its analytical significance, and the performance of FMC's diamide business in Asia.

    Answer

    Ronaldo Pereira, President, suggested that referenced prices in China are below production costs, indicating inventory dumping. Pierre Brondeau, Chairman and CEO, added that FMC's China diamide business is small and he is not overly concerned, promising a full strategy update next quarter. He clarified that overall diamide sales are up ~10%, with strong growth in Exirel offsetting a mid-single-digit decline in Rynaxypyr driven by Asia.

    Ask Fintool Equity Research AI